| abstract |
The present invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for SSEA4, a population of engineered cells expressing said CAR, and a pharmaceutical composition comprising said genetically modified cell expressing said CAR do. The pharmaceutical composition may be for use in the treatment of a cancer in a subject suffering from such cancer, wherein at least a subpopulation of cancerous cells of the cancer express SSEA4. |